证券日报网讯 2月12日，南卫股份发布公告称，控股股东李平于2月9日解除质押2，000，000股后又于 同日质押2，000，000股，累计质押9240万股，占其持股77.75%，占公司总股本31.97%。 （文章来源：证券日报） ...

江苏南方卫材医药股份有限公司关于 控股股东部分股份解除质押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至本公告披露日，江苏南方卫材医药股份有限公司（以下简称"公司"） 控股股东李平先生持有公司股份 118,841,048 股，占公司总股本的 41.12%。公 司控股股东李平先生及一致行动人李永平先生、李永中先生合计持有公司股份 136,560,415 股，占公司总股本的 47.25%。本次部分股份解除质押及再质押后， 李平先生累计质押公司股份 92,400,000 股，占其持有公司股份总数的 77.75%， 占公司总股本的 31.97%，李平先生及其一致行动人李永平先生、李永中先生累 计质押公司股份 102,039,338 股，占其合计持有公司股份总数的 74.72%，占公 司总股本的 35.30%。 公司于近日接到公司控股股东李平先生通知，获悉其所持部分公司股份办理 解除质押及再质押业务，具体事项如下： 一、上市公司股份解除质押 | 股东名称 | 李平 | | --- | --- ...

每经AI快讯，南卫股份2月12日晚间发布公告称，截至本公告披露日，江苏南方卫材医药股份有限公司 控股股东李平先生持有公司股份约1.19亿股，占公司总股本的41.12%。公司控股股东李平先生及一致行 动人李永平先生、李永中先生合计持有公司股份约1.37亿股，占公司总股本的47.25%。本次部分股份解 除质押及再质押后，李平先生累计质押公司股份9240万股，占其持有公司股份总数的77.75%，占公司 总股本的31.97%，李平先生及其一致行动人李永平先生、李永中先生累计质押公司股份约1.02亿股，占 其合计持有公司股份总数的74.72%，占公司总股本的35.3%。 每经头条（nbdtoutiao）——打造百万元级尊界的江淮，迎来葛卫东、方文艳联手投资：两人各掏10亿 元，公司股价应声大涨！复盘历史：牛散参与定增有赚也有亏 （记者 曾健辉） ...

Group 1 - The core viewpoint of the news is that Nanwei Co., Ltd. (603880) expects a net profit loss of 80 million yuan for the year 2025, which is an improvement compared to a loss of 191 million yuan in the previous year, primarily due to the market environment affecting its subsidiary Anhui Nanwei Medical's nitrile glove business, which has not fully released its production capacity [1] - For the first three quarters of 2025, the company reported revenue of 447 million yuan, a year-on-year decrease of 1.7%, and a net profit loss of 24.93 million yuan, with a debt ratio of 73.87% [1] - In the third quarter alone, the company achieved revenue of 141 million yuan, with a year-on-year increase in net profit loss of 16.59%, indicating ongoing pressure on overall profitability [1] Group 2 - The stock price of Nanwei Co., Ltd. has shown a volatile upward trend in the past week, closing at 6.79 yuan on February 10, 2026, with a single-day increase of 0.15% and a cumulative increase of 3.51% over the past five days [2] - On February 10, 2026, the main capital outflow was 6.0254 million yuan, accounting for 17.19% of the transaction volume, while on February 9, 2026, the main capital outflow was 84,600 yuan with a transaction volume of 16.1547 million yuan [2] - Technically, the stock price is approaching the upper Bollinger Band resistance level of 6.81 yuan, with short-term moving averages showing a bullish arrangement, although the MACD momentum is weak [2] Group 3 - According to the analysis from Xiangshang Artificial Intelligence Laboratory on February 10, 2026, Nanwei Co., Ltd. has a current price-to-book ratio of 7.51, which is significantly higher than the industry average, indicating a valuation premium, and there are concerns regarding profit quality with a net profit margin of -5.55% [3] - The report highlights the need to be cautious of high debt and cash flow volatility risks, while the narrowing of profit losses is seen as a positive signal, though the sustainability of profit improvement requires observation of subsequent quarterly data [3]

Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]

智通财经APP讯，南卫股份(603880.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为-8000万元，将出现亏损。 ...

Core Viewpoint - Nanwei Co., Ltd. (603880.SH) is expected to report a net loss attributable to shareholders of the parent company amounting to 80 million yuan for the fiscal year 2025, indicating a challenging financial outlook for the company [1] Financial Performance - The company anticipates a net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, to be approximately -82 million yuan for the fiscal year 2025 [1]

Financial Performance - The company expects a net loss of 80 million yuan for the fiscal year 2025, with a net profit attributable to the parent company after deducting non-recurring gains and losses projected at -82 million yuan [3]. - In the same period last year, the total profit was -200.86 million yuan, with a net profit attributable to the parent company of -190.67 million yuan, and a net profit after deducting non-recurring gains and losses of -187.73 million yuan [4]. - The earnings per share for the previous year was -0.66 yuan [4]. Operational Challenges - The poor performance in 2025 is primarily due to the underutilization of production capacity in the subsidiary's nitrile glove business, which was adversely affected by the industry market environment [7]. Earnings Forecast - The company emphasizes that the earnings forecast is based on preliminary calculations by the finance department and has not been audited by certified public accountants [9]. - There are no significant uncertainties affecting the accuracy of this earnings forecast as of the announcement date [8]. - The company advises investors to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data [9].

Group 1 - The company, Nanwei Co., Ltd., expects a net profit attributable to the parent company of -80 million yuan for the year 2025, indicating a loss [1] - In the same period last year, the net profit attributable to the parent company was -191 million yuan, showing an improvement in the loss situation [1]

南卫股份 江苏世纪同仁律师事务所 关于江苏南方卫材医药股份有限公司 2026年第二次临时股东会的法律意见书 致:江苏南方卫材医药股份有限公司 T PARTNERS 同仁律师事务所 江 苏 世 纪 同 仁 律 师 事 务 所 关于江苏南方卫材医药股份有限公司 2026 年第二次临时股东会的法律意见书 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 C 座 4 层 邮 编 : 210019 电话： +86 25-83304480 传真： +86 25-83329335 根据《中华人民共和国公司法》《中华人民共和国证券法》和中国证监会《上 市公司股东会规则》等法律法规和规范性文件以及《公司章程》的规定,本所受 贵公司董事会的委托,指派本所律师出席贵公司 2026年第二次临时股东会,并 就本次股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序以 及表决结果的合法有效性等事项出具法律意见。 法律意见书 法律意见书 南卫股份 法律意见书 为出具本法律意见书,本所律师对本次股东会所涉及的有关事项进行了审查, 查阅了本所律师认为出具法律意见所必须查阅的文件,并对有关问题进行了必要 的核查和验证。 本所律师 ...